Gallant Secures $18 Million to Launch Innovative Stem Cell Treatments for Pets

Gallant Advances Veterinary Care with $18 Million Series B Funding

Gallant, a trailblazing animal health biotechnology company, has successfully closed an impressive $18 million in Series B funding. This financing round, primarily led by Digitalis Ventures and supported by existing investors BOLD Capital and Hill Creek Partners, as well as new investor NovaQuest Capital Management, is set to revolutionize the treatment of pets suffering from chronic conditions through ready-to-use stem cell therapies.

With its innovative approach, Gallant aims to redefine veterinary care by tackling the fundamental causes of prevalent and often under-treated diseases in dogs and cats. Several key partners, including Digitalis Ventures and NovaQuest, recognize the significant impact Gallant could have in veterinary regenerative medicine.

A New Class of Therapy for Veterinary Medicine

Gallant's flagship product, currently in its pipeline, specifically targets refractory Feline Chronic Gingivostomatitis (FCGS). This cutting-edge therapy is poised for conditional FDA approval in early 2026, potentially becoming the first allogeneic stem cell therapy with FDA labeling for veterinary use. In addition to FCGS, Gallant is developing therapies aimed at treating conditions such as Canine and Feline Osteoarthritis (COA and FOA), Canine Atopic Dermatitis (CAD), and Feline Chronic Kidney Disease (CKD). These diseases often require urgent attention as traditional treatments primarily manage symptoms rather than addressing their root causes.

"We have been continually impressed by Gallant’s vision and capacity for execution. They address long-standing needs in animal health by utilizing proprietary technology to deliver transformative solutions to veterinarians and their patients," stated Dr. Cindy Cole, Technical Partner at Digitalis Ventures.

Expert Backing and Future Prospects

The participation of NovaQuest Capital Management in this funding round is especially notable given their previous experience with the first FDA-approved human allogeneic stem cell therapy, RYONCIL®. Their investment brings a wealth of expertise that can significantly bolster Gallant’s endeavor in the field of veterinary regenerative medicine.

According to Brian Axe, Partner at NovaQuest, "Regenerative medicine is on the brink of becoming mainstream. We have witnessed the success of allogeneic stem cell therapies in human healthcare, and now Gallant is bringing that high standard of science to treat animals with off-the-shelf stem cell therapies, targeting the core of various diseases."

Gallant’s approach is strategic and data-driven; research indicates that a mere 56% of veterinarians are satisfied with existing treatments for Canine Osteoarthritis and a disappointing 8% satisfaction for FCGS. This highlights a critical gap in effective animal healthcare, signaling demand for regenerative solutions like those offered by Gallant, which are designed to be ready-to-use, scientifically validated, and developed under FDA oversight.

A Mission to Transform Animal Health

At Gallant, the mission is clear: to innovate veterinary care so that it can effectively treat diseases instead of simply alleviating symptoms. Dr. Linda Black, CEO of Gallant, expressed her gratitude for the support received from investors who share a common vision. She emphasized the importance of obtaining FDA approval for human therapies as a crucial milestone and is eager to replicate this success for animal health.

Gallant's proprietary platform utilizes unique uterine-derived mesenchymal stem cells, aiming for the anticipated conditional approval of the FCGS therapy that could signal a new era in veterinary treatment by offering innovative solutions for previously difficult-to-treat conditions. The overarching goal remains ambitious—making stem cell therapies readily accessible to every pet that requires them.

About Gallant

Gallant is at the forefront of animal health innovation, generating a fresh category of veterinary medicine with a robust pipeline of off-the-shelf stem cell therapies. The company is led by industry pioneers who have extensive knowledge in the development, manufacturing, and commercialization of veterinarian solutions, focusing on restoring health and enhancing the quality of life for pets.

For more information about Gallant and its groundbreaking work, visit Gallant's website.